SCHEMBL10169402

SCHEMBL10169402

Cc1nc(Nc2ccc(N3CCOCC3)c(F)c2)c(C(N)=O)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.61
MAPK9 P45984 3/20 0.56
MAPK10 P53779 3/20 0.56
RET P07949 2/20 0.51
ROS1 P08922 2/20 0.51
FLT3 P36888 2/20 0.51
EML4 Q9HC35 1/20 0.51
ALK Q9UM73 1/20 0.51
HTT P42858 1/20 0.50
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
JAK3 P52333 2/20 0.46
LCK P06239 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169425 0.90 FLT3 (0.55) SYKMAPK9MAPK10RETROS1
SCHEMBL10169371 0.88 STAT6 (0.55) SYKEML4ALK
SCHEMBL10169331 0.81 BTK (0.57) SYKHPGDJAK3LCKJAK2
SCHEMBL13624768 0.79 SYK (0.70) SYKMAPK9MAPK10
SCHEMBL10169338 0.79 SYK (0.52) SYKRETROS1FLT3EML4
SCHEMBL13405517 0.78 PIM1 (0.57) SYKMAPK9MAPK10RETROS1
SCHEMBL12904966 0.78 SYK (0.65) SYKMAPK9MAPK10JAK3
SCHEMBL10169403 0.77 SYK (0.44) SYKMAPK9MAPK10ALDH1A1LMNA
SCHEMBL16195714 0.77 FLT3 (0.66) SYKMAPK9MAPK10RETROS1
SCHEMBL1353854 0.76 SYK (1.00) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT SYK 22/4885MAPK9 129/4885MAPK10 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.